Trinity Biotech (TRIB)
0.77
-0.05 (-6.10%)
At close: Jan 14, 2025, 3:59 PM
0.84
9.09%
Pre-market Jan 15, 2025, 05:03 AM EST
undefined% (undefined)
| Bid | 0.77 |
| Market Cap | 8.76M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.2 |
| PE Ratio (ttm) | -0.35 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.92 |
| Volume | 124,487 |
| Avg. Volume (20D) | 195,385 |
| Open | 0.82 |
| Previous Close | 0.82 |
| Day's Range | 0.76 - 0.85 |
| 52-Week Range | 0.75 - 3.55 |
| Beta | undefined |
About TRIB
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; ...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 21, 1992
Employees 380
Stock Exchange NASDAQ
Ticker Symbol TRIB
Website https://www.trinitybiotech.com
Next Earnings Release
Trinity Biotech is scheduled to release its earnings on Apr 3, 2025,
before market opens.
Analysts project revenue of $18.50M, reflecting a 37.77% YoY growth and earnings per share of -0.47, making a -34.72% decrease YoY.
Analysts project revenue of $18.50M, reflecting a 37.77% YoY growth and earnings per share of -0.47, making a -34.72% decrease YoY.
2 months ago ·
Source
+5.46%
Trinity Biotech shares are trading higher after th...
Unlock content with
Pro Subscription
3 months ago ·
Source
+13.33%
Trinity Biotech shares are trading higher after the company announced it completed its first pre-pivotal clinical trial in Europe for its continuous glucose monitor technology.
